Floatz logo

AQUOCOBALAMIN

BRCA1 Mutation

General Oncology, Inc.Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the BRCA1 Mutation cohort.

Asset / SponsorPhaseRating
Ovitrelle
University Hospital, Ghent
Phase 4BB
Olaparib
GBG Forschungs GmbH
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
The University of Texas Health Science Center at San Antonio
Phase 3B
Niraparib
University of California, San Francisco
Phase 2B
Irinotecan
University of California, San Francisco
Phase 2B

View all 25 →

Same molecule, other indications

AQUOCOBALAMIN is also rated in:

breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic acinar cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
breast adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →